NSU-MD Faculty Articles
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
Publication Title
British journal of haematology
Publisher
Wiley-Blackwell Publishing Ltd.
ISSN
0007-1048
Publication Date
8-1-2016
Keywords
ADP-ribosyl Cyclase 1, Aged, Antibodies, Monoclonal, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Multiple Myeloma, Salvage Therapy, Treatment Outcome
DOI
10.1111/bjh.13776
Volume
174
Issue
3
First Page
473
Last Page
477
Disciplines
Medicine and Health Sciences
NSUWorks Citation
Alici, Evren; Chrobok, Michael; Lund, Johan; Ahmadi, Tahamtan; Khan, Imran; Duru, Adil D; and Nahi, Hareth, "Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach." (2016). NSU-MD Faculty Articles. 70.
https://nsuworks.nova.edu/hpd_md_facarticles/70
